Affimed Reports First Patient Dosing of AFM28 in the P-I Study for the Treatment of CD123-Positive Acute Myeloid Leukemia
Shots:
- The first patient has been dosed in a P-I open-label, first-in-human dose escalation study (AFM28-101) evaluating the safety, tolerability, PK & PD of AFM28 monotx. in patients with CD123+ r/r AML
- The purpose of the study is to establish the MTD & one or more RP2D. Additionally, NK cells are efficiently directed by AFM28 to CD123+ leukemic cells, incl. blasts & leukemic stem & progenitor cells resulting in their depletion in samples from patients with AML & MDS
- AFM28 is a tetravalent bispecific CD123- and CD16A-binding innate cell engager (ICE) that has been developed from Affimed’s Redirected Optimized Cell Killing platform. The company also plans to develop AFM28 in combination with allogeneic NK cell therapy
Ref: affimed | Image: affimed
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
